Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause

References

• Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Maturitas. 2014;79:349–354.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass MLS. Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. J Sex Med. 2014;11:2865–2872.
   PubMed Web of Science ®Google Scholar
• Kim HK, Kang SY, Chung YJ, et al. The recent review of the genitourinary syndrome of menopause. J Menopausal Med. 2015;21:65–71.
   PubMedGoogle Scholar
• Simon JA, Komi J. Vulvovaginal atrophy (VVA) negatively impacts sexual function, psychosocial well-being, and partner relationships. Presented at: 18th Annual Meeting of The North American Menopause Society; 2007 Oct 3–6; Dallas, TX. LB-10. Menopause 2007;14:1107.
   Google Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric. 2014;17:3–9.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Koehler KF. Oestrogen receptors and selective oestrogen receptor modulators: molecular and cellular pharmacology. Basic Clin Pharmacol Toxicol. 2005;96:15–25.
   PubMed Web of Science ®Google Scholar
• Smith CL, Nawaz Z, O’Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen,4-hydroxytamoxifen. Mol Endocrinol. 1997;11:657–666.
   PubMed Web of Science ®Google Scholar
• Burich RA, Mehta NR, Wurz GT, et al. Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Menopause. 2012;19:96–103.
   PubMed Web of Science ®Google Scholar
• Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100:3975–4011.
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19:109–150.
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Reeves G. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543–1551.
   PubMed Web of Science ®Google Scholar
• Palacios S, Mejía A, Neyro JL. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015;18 Suppl 1:23–29.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Leone Roberti Maggiore U, Athanasiou S, et al. Histological study on the effects of microablative fractional CO2 laser on atrophic vaginal tissue: an ex vivo study. Menopause. 2015;22:845–849.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Zerbinati N, et al. A 12-week treatment with fractional CO2 laser for vulvovaginal atrophy: a pilot study. Climacteric. 2014;17:363–369.
   PubMed Web of Science ®Google Scholar
• Salvatore S, Nappi RE, Parma M, et al. Sexual function after fractional microablative CO₂ laser in women with vulvovaginal atrophy. Climacteric. 2015;18:219–225.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Torelli MG, Martella L, et al. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence. Climacteric. 2015;18 Suppl 1:43–48.
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause. Climacteric. 2015;18:757–763.
   PubMed Web of Science ®Google Scholar
• Vicariotto F, Raichi M. Technological evolution in the radiofrequency treatment of vaginal laxity and menopausal vulvo-vaginal atrophy and other genitourinary symptoms: first experiences with a novel dynamic quadripolar device. Minerva Ginecol. 2016;68:225–236.
   PubMed Web of Science ®Google Scholar
• [cited 2016 April 12]. Available from: http://www.chemspider.com/Chemical-Structure.2300501.html?rid=158fce9e-fe54-43ed-b961-ba4fe77ff9c5
   Google Scholar
• Bachmann GA, Komi JO; The Ospemifene Study Group. Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. Menopause. 2010;17:480–486.
   PubMed Web of Science ®Google Scholar
• Portman DJ, Bachmann GA, Simon JA; Ospemifene Study Group. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy. Menopause. 2013;20:623–630.
   PubMed Web of Science ®Google Scholar
• Portman D, Palacios S, Nappi RE, et al. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: A randomised, placebo-controlled, phase III trial. Maturitas. 2014;78:91–98.
   PubMed Web of Science ®Google Scholar
• Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 2000;18:3172–3186.
   PubMed Web of Science ®Google Scholar
• Qu Q, Zheng H, Dahllund J, et al. Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology. 2000;141:809–820.
   PubMed Web of Science ®Google Scholar
• DeGregorio MW, Wurz GT, Taras TL, et al. Pharmacokinetics of (deaminohydroxy)toremifene in humans: a new, selective estrogen-receptor modulator. Eur J Clin Pharmacol. 2000;56:469–475.
   PubMed Web of Science ®Google Scholar
• Koskimies P, Katila K, Lammintausta R, et al. Oral bioavailability of ospemifene improves with food intake. Int J Clin Pharmacol Ther. 2013;51:787–794.
   PubMed Web of Science ®Google Scholar
• Gennari L. Ospemifene hormos. Curr Opin Investig Drugs. 2004;5:448–455.
   PubMedGoogle Scholar
• Lehtinen T, Tolonen A, Turpeinen M, et al. Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. Biopharm Drug Dispos. 2013;34:387–395.
   PubMed Web of Science ®Google Scholar
• Michael H, Härkönen PL, Kangas L, et al. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. Br J Pharmacol. 2007;151:384–395.
   PubMed Web of Science ®Google Scholar
• Labrie F, Martel C, Gauthier S, et al. Effect of toremifene and ospemifene, compared to acolbifene, on estrogen-sensitive parameters in rat and human uterine tissues. Horm Mol Biol Clin Invest. 2010;1:139–146.
   PubMedGoogle Scholar
• Rando G, Horner D, Biserni A, et al. An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals. Mol Endocrinol. 2010;24:735–744.
   PubMed Web of Science ®Google Scholar
• Zheng H, Kangas L, Härkönen PL. Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus. J Steroid Biochem Mol Biol. 2004;88:143–156.
   PubMed Web of Science ®Google Scholar
• Wurz GT, Read KC, Marchisano-Karpman C, et al. Ospemifene inhibits the growth of dimethylbenzanthracene induced mammary tumors in Sencar mice. J Steroid Biochem Mol Biol. 2005;97:230–240.
   PubMed Web of Science ®Google Scholar
• Ylikorkala O, Cacciatore B, Halonen K, et al. Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. Menopause. 2003;10:440–447.
   PubMed Web of Science ®Google Scholar
• Rutanen EM, Heikkinen J, Halonen K, et al. Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause. 2003;10:433–439.
   PubMed Web of Science ®Google Scholar
• Komi J, Heikkinen J, Rutanen EM, et al. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol Endocrinol. 2004;18:152–158.
   PubMed Web of Science ®Google Scholar
• Komi J, Lankinen KS, Härkönen P, et al. Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. Menopause. 2005;12:202–209.
   PubMed Web of Science ®Google Scholar
• Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric. 2015;18:226–232.
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Bachmann GA, Koninckx PR; the Ospemifene Study group. Ospemifene 12-month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric. 2014;17:173–182.
   PubMed Web of Science ®Google Scholar
• Simon JA, Lin VH, Radovich C, et al.; the Ospemifene Study Group. One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus. Menopause. 2013;20:418–427.
   PubMed Web of Science ®Google Scholar
• Constantine GD, Goldstein SR, Archer DF. Endometrial safety of ospemifene: results of the phase 2/3 clinical development program. Menopause. 2015;22:36–43.
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013;20:888–902.
   PubMed Web of Science ®Google Scholar
• Parish SJ, Nappi RE, Krychman ML, et al. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int J Womens Health. 2013;5:437–447.
   PubMedGoogle Scholar
• Winneker RC, Harris HA. Progress and prospects in treating postmenopausal vaginal atrophy. Clin Pharmacol Ther. 2011;89:129–132.
   PubMed Web of Science ®Google Scholar
• Simon JA, Nappi RE, Kingsberg SA, et al. Clarifying Vaginal Atrophy’s Impact on Sex and Relationships (CLOSER) survey: emotional and physical impact of vaginal discomfort on North American postmenopausal women and their partners. Menopause. 2014;21:137–142.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kingsberg S, Maamari R, et al. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J Sex Med. 2013;10:2232–2241.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Vaginal health: insights, views & attitudes (VIVA): results from an international survey. Climacteric. 2012;15:36–44.
   PubMed Web of Science ®Google Scholar
• Kingsberg SA, Wysocki S, Magnus L, et al. Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE (REal Women’s VIews of Treatment Options for Menopausal Vaginal ChangEs) survey. J Sex Med. 2013;10:1790–1799.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Palacios S, Panay N, et al. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric. 2016;19:188–197.
   PubMed Web of Science ®Google Scholar
• Bruyniks N, Nappi RE, Castelo-Branco C, et al. Effect of ospemifene on moderate or severe symptoms of vulvar and vaginal atrophy. Climacteric. 2016;19:60–65.
   PubMed Web of Science ®Google Scholar
• Nappi RE, Panay N, Bruyniks N, et al. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric. 2015;18:233–240.
   PubMed Web of Science ®Google Scholar
• Taras TL, Wurz GT, DeGregorio MW. In vitro and in vivo biologic effects of ospemifene (FC-1271a) in breast cancer. J Steroid Biochem Mol Biol. 2001;77:271–279.
   PubMed Web of Science ®Google Scholar
• Unkila M, Kari S, Yatkin E, et al. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. J Steroid Biochem Mol Biol. 2013;138:107–115.
   PubMed Web of Science ®Google Scholar
• Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013;78:1273–1280. Menopause. 2012;19:96–103.
   PubMed Web of Science ®Google Scholar
• Biglia N, Bounous VE, Sgro LG, et al. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer. 2015;15:413–420.
   PubMed Web of Science ®Google Scholar
• Osphena™ (ospemifene). [prescribing information]. Florham Park (NJ): Shionogi, Inc; 2013.
   Google Scholar